Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Lung Cancer Metastatic × Ipilimumab × Thoracic × Clear all

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 70 Lung Neoplasms 27 Small Cell Lung Carcinoma 17 Melanoma 15 Mesothelioma 11 Neoplasms 10 Colorectal Neoplasms 9 Carcinoma, Renal Cell 8 Squamous Cell Carcinoma of Head and Neck 7 Mesothelioma, Malignant 7 Carcinoma, Transitional Cell 7 Diabetes Mellitus, Insulin-Dependent, 12 6 Urinary Bladder Neoplasms 5 Ovarian Neoplasms 5 Neoplasm Metastasis 5 Endometrial Neoplasms 5 Carcinoma, Hepatocellular 5 Uterine Cervical Neoplasms 4 Triple Negative Breast Neoplasms 4 Stomach Neoplasms 4 Pancreatic Neoplasms 4 Liver Neoplasms 4 Kidney Neoplasms 4 Brain Neoplasms 4 Carcinoma, Merkel Cell 3 Skin Neoplasms 2 Sarcoma 2 Prostatic Neoplasms 2 Lung Diseases 2 Head and Neck Neoplasms 2

Interventions

tremelimumab 1 regramostim 1 osimertinib 1 evolocumab 1 durvalumab 1 Surgical Instruments 1 Radiotherapy 1 Radiation 1 Nivolumab 1 Needles 1 MLN 8237 1 Ipilimumab 1 Granulocyte-Macrophage Colony-Stimulating Factor 1 Cisplatin 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05144529 2025-04-17

TOP2101

Duke University

Phase 2 Active not recruiting

Lung Cancer Metastatic

Data powered by HemOnc (CC BY 4.0) Colophon ⚡